STOCK TITAN
  1. Home
  2. Sec-filings
  3. SONN
  4. [8-K] Sonnet BioTherapeutics Holdings, Inc. Reports Material Event

[8-K] Sonnet BioTherapeutics Holdings, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock SONN logo
Sonnet Biotherapeutc Hldng Inc

NASDAQ:SONN

SONN Rankings

#10525 Ranked by Market Cap
N/A Ranked by Dividends

SONN Latest News

Jul 14, 2025
Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy
May 1, 2025
Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit
Apr 16, 2025
Sonnet Releases Virtual Investor "What This Means" Segment
Apr 4, 2025
Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose
Apr 1, 2025
Sonnet Announces Release of Corporate Update Video

SONN Latest SEC Filings

Jul 15, 2025
[Form 4] Sonnet BioTherapeutics Holdings, Inc. Insider Trading Activity
Jul 15, 2025
[Form 4] Sonnet BioTherapeutics Holdings, Inc. Insider Trading Activity
Jul 15, 2025
[Form 4] Sonnet BioTherapeutics Holdings, Inc. Insider Trading Activity
Jul 15, 2025
[Form 4] Sonnet BioTherapeutics Holdings, Inc. Insider Trading Activity
Jul 15, 2025
[Form 4] Sonnet BioTherapeutics Holdings, Inc. Insider Trading Activity

SONN Stock Data

16.72M
3.04M
1.58%
3.06%
3.03%
Biotechnology
Pharmaceutical Preparations
Link
United States
PRINCETON